[1] |
Granich R, Gupta S, Hersh B, et al. Trends in AIDS deaths, new infections and ART coverage in the top 30 countries with the highest AIDS mortality burden; 1990-2013[J]. PLoS One, 2015, 10(7):e0131353.
|
[2] |
陈志敏, 何浩岚, 刘波, 等. 2013—2018年广州市某医院HIV感染住院患者全因病死率及死亡原因分析[J]. 国际病毒学杂志, 2021, 28(6):453-458.
|
|
Chen ZM, He HL, Liu B, et al. Analysis on the all-cause mortality and causes of death among HIV-infected inpatients in a hosptial in Guangzhou, 2013-2018[J]. Int J Virol, 2021, 28(6):453-458.
|
[3] |
Larsson M, Nguyen LH, Wertheim HF, et al. Clinical characteristics and outcome of penicillium marneffei infection among HIV-infected patients in northern Vietnam[J]. AIDS Res Ther, 2012, 9(1):24.
doi: 10.1186/1742-6405-9-24
pmid: 22897817
|
[4] |
何小庆, 鲁雁秋, 周怡宏, 等. 重庆地区56例AIDS合并播散性马尔尼菲篮状菌病患者临床特征及死亡危险因素分析[J]. 传染病信息, 2018, 31(6):521-524.
|
|
He XQ, Lu YQ, Zhou YH, et al. Clinical characteristics and death risk factors analysis of 56 AIDS patients with disseminated talaromycosis marneffei in Chongqing[J]. Infectious Disease Information, 2018, 31(6):521-524.
|
[5] |
中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华内科杂志, 2021, 60(12):1106-1128.
|
|
AIDS and hepatitis C study group, infectious disease branch, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12):1106-1128.
|
[6] |
李凌华, 唐小平, 蔡卫平. 101例艾滋病合并马尔尼菲青霉病的临床研究[J]. 中国艾滋病性病, 2008, 14(1):12-14,20.
|
|
Li LH, Tang XP, Cai WP. A clinical study on 101 AIDS cases complicated with penicilliosis marneffei[J]. Chin J AIDS & STD, 2008, 14(1):12-14,20.
|
[7] |
陈涛, 蒋忠胜, 李敏基, 等. CD4+T淋巴细胞、血清转氨酶及血小板水平对马尔尼菲蓝状菌病患者预后的预测价值[J]. 中国感染控制杂志, 2018, 17(12):1098-1102.
|
|
Chen T, Jiang ZS, Li MJ, et al. Predictive value of CD4+ T lymphocyte, serum aminotransferase, and platelet in the prognosis of patients with talaromycosis marneffeii[J]. Chin J Infect Control, 2018, 17(12):1098-1102.
|
[8] |
Qin Y, Zhou Y, Lu Y, et al. Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis[J]. Mycoses, 2021, 64(2):203-211.
doi: 10.1111/myc.13206
pmid: 33141968
|
[9] |
何凯茵, 冯理智, 梁志伟, 等. 血清半乳甘露聚糖试验在诊断艾滋病合并马尔尼菲青霉菌病中的价值探讨[J]. 广州医科大学学报, 2016, 44(3):21-24.
|
|
He KY, Feng LZ, Liang ZW, et al. Value of serum galactomannan test in diagnosis of AIDS complicated with penicilliosis marneffei[J]. Acad J Guangzhou Med Coll, 2016, 44(3):21-24.
|
[10] |
梁欣, 马卫国, 黎灿, 等. APACHEⅡ/Ⅲ与SAPSⅡ评分系统对艾滋病合并播散性马尔尼菲青霉菌病患者病情预后评估的价值[J]. 中国实用医药, 2012, 7(27):12-14.
|
|
Liang X, Ma WG, Li C, et al. Comparison of APACHEⅡ/Ⅲ and SAPSⅡ in evaluating the severity and prognosis of patients with disseminated penicilliosis marneffei associated AIDS[J]. China Pract Med, 2012, 7(27):12-14.
|
[11] |
Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis[J}. N Engl J Med, 2017, 376(24):2329-2340.
doi: 10.1056/NEJMoa1613306
URL
|
[12] |
袁锡华, 曹存巍. 伏立康唑与两性霉素B治疗AIDS合并马尔尼菲蓝状菌病的疗效及安全性对比[J]. 广西医科大学学报, 2019, 36(2):262-265.
|
|
Yuan XH, Cao CW. Comparison of efficacy and safety of voriconazole and amphotericin B in the treatment of AIDS combined with talaromycosis marneffei[J]. J Guangxi Med Univ, 2019, 36(2):262-265.
|
[13] |
Sun J, Sun W, Tang Y, et al. Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection[J]. BMC Infect Dis, 2021, 21(1):514.
doi: 10.1186/s12879-021-06232-2
pmid: 34074256
|
[14] |
Ying RS, Le T, Cai WP, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017[J]. HIV Med, 2020, 21(11):729-738.
doi: 10.1111/hiv.13024
pmid: 33369035
|
[15] |
黄丽芬, 邓子德, 叶晓新, 等. 345例艾滋病死亡病例的医院感染状况分析[J]. 中国感染控制杂志, 2013, 12(3):178-181.
|
|
Huang LF, Deng ZD, Ye XX, et al. Healthcare-associated infection in 345 HIV/AIDS death cases[J]. Chin J Infect Control, 2013, 12(3):178-181.
|